iqvia semaglutide tirzepatide prescriptions q3 2024 This Week in GLP-1: Apotex Clears FDA, Novo Cuts Wegovy, and Canada's Generic Pricing Framework Global Medicines Outlook 2024-2028 |

Once reconstituted, refrigeration is required

Type 1 5-alpha reductase is the enzyme that produces follicle-damaging dihydrotestosterone (DHT) in hair follicles

You're likely a reasonable candidate if: You've been symptomatic for more than 12 weeks with confirmed or highly probable prior SARS-CoV-2 infection Standard care has not produced adequate improvement You have a clear symptom cluster that maps to one or more of the mechanisms above You're willing to undergo baseline labs and ongoing clinical monitoring You understand that peptide therapy is an emerging not established intervention for this indication You may need to address other issues first if: Active autoimmune conditions are not yet stabilised You have unmanaged cardiovascular disease You're currently immunosuppressed for another reason You haven't yet tried evidence-based long COVID rehabilitation approaches The most important step is working with a clinician who understands both long COVID pathophysiology and peptide pharmacology not one who simply offers a generic protocol

Escalation of Dosing After the initial period, the dose is generally increased incrementally, typically every four weeks, depending on how well the patient tolerates the medication